In a World Racing Toward Net-Zero, Researchers Propose Turning the Most Controversial Crop on Earth Into the Most Valuable One
Cannabis Plant Could Power Your Car AND Transform Modern Medicine: Scientists Propose Revolutionary Dual-Use Platform
In a World Racing Toward Net-Zero, Researchers Propose Turning the Most Controversial Crop on Earth Into the Most Valuable One
Published: Frontiers in Plant Science | Volume 17 | May 20, 2026
DOI: 10.3389/fpls.2026.1833491
Full text: https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2026.1833491/full
AUGUSTA, GA, May 22, 2026 /24-7PressRelease/ — In a paradigm-shifting hypothesis published in Frontiers in Plant Science, two Augusta University faculty scientists, working through their biotechnology startup Medicinal Cannabis of Georgia LLC, have proposed a bold, patented framework that could transform Cannabis sativa into one of the most powerful tools in the global fight against climate change, while simultaneously advancing the frontiers of medicine across a broad range of diseases and therapeutic applications.
The study, titled “Harnessing Cannabis sativa as a Dual-Use Platform for Biohydrogen Production and Pharmaceutical Synthesis: A Hypothesis and Theory,” introduces a novel biorefinery model in which genetically engineered cannabis plants simultaneously produce clean green hydrogen fuel and high-value therapeutic cannabinoids, all from the same crop, at the same time.
ACADEMIC INNOVATION MEETS ENTREPRENEURSHIP
The research was conceived and developed by Dr. Babak Baban and Dr. Lei P. Wang, both full-time faculty at Augusta University through their co-founded biotechnology company, Medicinal Cannabis of Georgia LLC, which operates within Augusta University’s BioLife Sciences Incubator. This work exemplifies the spirit of academic entrepreneurship: transforming visionary scientific ideas into patented, commercially viable innovations that benefit society.
“This is what the intersection of science and entrepreneurship looks like. We asked ourselves why choose between green energy and green medicine when the same plant can deliver both? And then we went ahead and patented the answer.”, Dr. Babak Baban
THE BIG IDEA: ONE PLANT, TWO REVOLUTIONS
The world needs clean energy. The world needs better medicines for a wide range of diseases and conditions. Drs. Baban and Wang believe one plant can deliver both, and they have the patent to prove it.
Using advanced synthetic biology techniques, the researchers propose engineering the cannabis chloroplast, the plant’s energy-producing organelle, to redirect photosynthetic electron flow toward hydrogen production. By inserting an oxygen-protected hydrogenase enzyme into the chloroplast genome, the plant can generate molecular hydrogen (H₂) during its vegetative growth phase, while later producing cannabinoids such as CBD and THC during flowering.
The result is a Tripartite Circular Economy, a zero-waste, three-phase harvest model:
Phase 1: Capture clean green hydrogen during peak vegetative growth
Phase 2: Harvest therapeutic cannabinoids and terpenes during flowering
Phase 3: Process remaining biomass into industrial fiber, textiles, and carbon-sequestering biochar
Nothing is wasted. Everything has value.
WHY CANNABIS? THE NUMBERS ARE COMPELLING
Unlike algae-based biohydrogen systems — which require expensive reactors and consume their own biomass — cannabis offers a uniquely superior platform:
Biomass yield 2-3x higher than green algae or cyanobacteria
Net Present Value $500K–$2M per hectare over 20 years, 3-5x higher than competing systems
Break-even in just 3-5 years, compared to 7-12 years for algae-based systems
$10 billion+ in existing controlled-environment agriculture (CEA) infrastructure already in place
Zero food competition, unlike corn-based ethanol, cannabis does not displace food crops
The global industrial hemp market, currently valued at $7.5 billion, is projected to reach $27.7 billion by 2033, providing a powerful economic foundation for this dual-use model.
WHAT THIS MEANS FOR THE PLANET AND FOR MEDICINE
Hydrogen is widely regarded as the fuel of the future — clean, efficient, and carbon-free at the point of use. However, current biological hydrogen production methods have struggled with economic viability. This cannabis-based platform could change that equation entirely — by making the economics work through pharmaceutical revenue that effectively subsidizes the cost of green hydrogen production.
“The pharmaceutical value of cannabinoids underwrites the energy production. This is not just a science story — it is an economic story. The cannabis biorefinery model makes green hydrogen commercially viable in a way that nothing else has achieved,” Dr. Lei P. Wang
Beyond clean energy, the cannabinoid component of this platform holds broad therapeutic promise across multiple disease areas, including neurology, oncology, immunology, and pain management, reflecting the diverse and expanding research portfolio of Medicinal Cannabis of Georgia LLC.
LOOKING AHEAD
The researchers acknowledge that translating this hypothesis into practice will require overcoming significant technical and regulatory challenges, including establishing stable chloroplast transformation protocols for cannabis and navigating the complex regulatory landscape governing genetically modified cannabis across jurisdictions. They propose a phased development roadmap beginning with proof-of-concept studies in model plant systems before progressing to cannabis-specific engineering.
Drs. Baban and Wang have proactively reached out to major pharmaceutical and energy industry partners to explore collaborative development of this platform, reflecting their commitment to translating this vision into commercial and environmental reality.
ABOUT THE PUBLICATION
Wang LP and Baban B (2026). Frontiers in Plant Science 17:1833491.
doi: 10.3389/fpls.2026.1833491
Full text: https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2026.1833491/full
ABOUT MEDICINAL CANNABIS OF GEORGIA LLC
Medicinal Cannabis of Georgia LLC is a research-focused biotechnology startup co-founded by Dr. Babak Baban and Dr. Lei P. Wang, operating within Augusta University’s BioLife Sciences Incubator. The company focuses on developing innovative cannabinoid-based therapeutic and energy platforms at the intersection of medicine, synthetic biology, and sustainable technology, spanning multiple therapeutic areas including neurology, oncology, immunology, and clean energy. All intellectual property, including provisional patent No. 63916615, is owned by Medicinal Cannabis of Georgia LLC.
ABOUT AUGUSTA UNIVERSITY
Augusta University is a public research university and academic medical center in Augusta, Georgia. Through its BioLife Sciences Incubator and research infrastructure, Augusta University supports faculty entrepreneurship and the translation of academic innovation into real-world commercial and societal impact.
MEDIA CONTACT
Dr. Babak Baban, PhD, MPH, MBA, FAHA
Professor and Associate Dean for Research
Center for Excellence in Research, Scholarship & Innovation (CERSI)
The Dental College of Georgia
Departments of Neurology and Surgery/The Medical College of Georgia
Augusta University
Regents’ Entrepreneur
Co-Founder, Medicinal Cannabis of Georgia LLC
Email: babak@medicinalcannabisofgeorgia.com | bbaban@augusta.edu
Phone: (706) 721-2032
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
